Lorus Therapeutics: New CEO, new focus for lead candidate
This article was originally published in Scrip
Executive Summary
When William Rice was brought in as a consultant to take a look at Lorus Therapeutics and its pipeline of cancer drug candidates, he saw an opportunity to advance the Canadian company's lead small molecule LOR-253 in a faster, targeted way.